Free Case Review for Affected Families
Markovits, Stock & DeMarco, LLC, a law firm experienced in complex and class action litigation, is investigating potential claims arising from the nationwide recall of Children’s Ibuprofen Oral Suspension manufactured by Strides Pharma, Inc. after the company received complaints of a gel-like mass and black particles found in the product.
Strides Pharma, Inc., headquartered in India, has recalled approximately 89,592 bottles of its Children’s Ibuprofen Oral Suspension, USP, 100 mg per 5 mL, sold in 4 FL OZ (120 mL) bottles. The product was manufactured for Taro Pharmaceuticals USA, Inc. and distributed nationwide. The recalled bottles carry lot numbers 7261973A and 7261974A with an expiry date of January 31, 2027.[1]
On March 16, 2026, the FDA classified this action as a Class II recall, meaning that use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote.[2]
If your child consumed the recalled Children’s Ibuprofen Oral Suspension and experienced health complications, or if you purchased the recalled product, you may be entitled to compensation. Our firm is actively assisting families with documenting injuries, preserving product evidence, and evaluating legal claims.
Who May Have a Claim
- Families whose children experienced adverse health effects after consuming the recalled ibuprofen product
- Children who exhibited symptoms such as gastrointestinal distress, vomiting, or allergic reactions after taking the medication
- Parents who purchased recalled Children’s Ibuprofen Oral Suspension (lot numbers 7261973A or 7261974A) and incurred economic losses
- Families who required medical monitoring or treatment due to potential exposure to foreign substances in the product
Potential Compensation
- Medical bills, emergency treatment, and future medical monitoring
- Pain and suffering and emotional distress
- Costs of replacement medication and related expenses
- Reimbursement for economic loss tied to the recall
- Long-term health impacts, if any
What Parents Should Do Now
FIRST AND FOREMOST: Seek immediate medical attention if your child shows any symptoms of concern after taking the recalled product. Your child’s health is the absolute priority.
- Stop using the recalled product immediately. Preserve all bottles, packaging, and receipts.
- Document all symptoms, medical visits, and treatment plans.
- Check lot numbers on any Children’s Ibuprofen Oral Suspension in your home (affected lots: 7261973A and 7261974A, expiry January 31, 2027).
- Follow all medical guidance and seek immediate evaluation for concerning symptoms.
- Do not provide statements to manufacturers or insurers without legal counsel.
Contact Us for a Free, Confidential Case Review
To discuss your child’s symptoms, rights, or potential compensation related to the Children’s Ibuprofen recall, please contact attorney Justin C. Walker at (513) 651-3700, email [email protected], or submit a Case Evaluation Request through the form below.
Frequently Asked Questions
What is the recall about?
Strides Pharma, Inc. recalled approximately 89,592 bottles of Children’s Ibuprofen Oral Suspension after receiving complaints about a gel-like mass and black particles found in the product. The FDA classified this as a Class II recall.
Does my child need severe symptoms to have a claim?
Not necessarily. Claims may exist for medical monitoring, economic losses, and product replacement even without hospitalization.
How do I know if I have the recalled product?
Check the lot number on your bottle of Children’s Ibuprofen Oral Suspension, USP, 100 mg per 5 mL. The affected lot numbers are 7261973A and 7261974A, with an expiration date of January 31, 2027.
What if my child took the medication but seems fine?
Consult your pediatrician. Foreign substances in medication can pose risks that may not be immediately apparent. Medical evaluation is far more important than legal consultation at this stage.
[1]https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
[2]https://www.usatoday.com/story/money/2026/03/18/childrens-ibuprofen-recall-strides-pharma/